All In Biotech

Drug Trial Radar · NCT07100119

A Study of LY4256984 in Participants With Sporadic Amyotrophic Lateral Sclerosis

A Multiple Ascending Dose Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intrathecally Administered LY4256984 in Participants With Sporadic Amyotrophic Lateral Sclerosis

Last checked: Nov 20, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

36

Planned (sponsor's estimate)

Start

Aug 5, 2025

Primary completion

Aug 2027

Study completion Sep 2027

Sponsor

Lead sponsor
Eli Lilly and CompanyEli Lilly (LLY)
Sponsor type
Industry
First posted
Aug 3, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Basic science
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate how well LY4256984 is tolerated and what side effects may occur in participants with sporadic amyotrophic lateral sclerosis (ALS). The study drug will be administered intrathecally (IT) into the spine. Blood tests will be performed to check how much LY4256984 gets into the bloodstream and how long it takes the body to eliminate it.

Conditions

  • ALS (Amyotrophic Lateral Sclerosis)

Interventions

  • LY4256984Drug

    Administered IT

  • PlaceboDrug

    Administered IT

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs), Serious Adverse Event(s) (SAEs), and Adverse Event(s) (AEs) Considered by the Investigator to be Related to Study Drug AdministrationTime frame: Baseline up to Approximately Day 253

Locations

12 sites in 5 countries. Site status is shown where the registry gives one.

  • UZ Leuven

    Leuven, Belgium · Recruiting

  • Heritage Medical Research Clinic

    Calgary, Canada · Recruiting

  • Walter Mackenzie Health Sciences Centre

    Edmonton, Canada · Not yet recruiting

  • London Health Sciences Centre

    London, Canada · Recruiting

  • Montreal Neurological Institute and Hospital

    Montreal, Canada · Recruiting

  • Sunnybrook Research Institute

    Toronto, Canada · Recruiting

  • Universitätsklinikum Schleswig-Holstein

    Lübeck, Germany · Recruiting

  • Universitätsmedizin Rostock Sektion für Translationale Neurodegeneration "Albrecht Kossel" Klinik und Poliklinik für Neurologie

    Rostock, Germany · Not yet recruiting

  • Universitätsklinikum Ulm

    Ulm, Germany · Recruiting

  • Universitair Medisch Centrum Utrecht

    Utrecht, Netherlands · Recruiting

  • Hospital Universitario de Bellvitge

    L'Hospitalet de Llobregat, Spain · Recruiting

  • Hospital Universitari i Politecnic La Fe

    Valencia, Spain · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.